Mid-Atlantic Bio

Baltimore-Based CSA Medical Raises $20.5 Million in Second Round

Baltimore — CSA Medical, the Baltimore-based developer of a spray cryotherapy device that freeze and destroy unwanted tissue inside the body, said on Thursday it has raised $20.5 million in its second round of funding, co-led by Intersouth Partners and First Analysis. Other investors in the round included S.V. Life Sciences, Rose Park, and Blue Heron Capital. The company will use the proceeds to fund post-market clinical studies and ongoing development activities. “This partnership and funding will support the launch of our new platform, expanded utilization and further development of new clinical applications,” said CEO Bill Floyd. CSA’s technology is currently being used at more than 80 cancer centers and academic teaching hospitals to treat esophageal disease.
http://www.csamedical.com
http://www.businesswire.com/news/home/20111215005360/en/CSA-Medical%E2%84%A2-Completes-20.5-Million-Series-Financing

Baltimore-Based CSA Medical Raises $12.6 Million in First Round

Baltimore — CSA Medical, a Baltimore-based developer of devices that flash freeze and treat diseased tissue inside the body, said on Tuesday it has raised $12.6 million in its first round of funding, which included a new investment from Blue Heron Capital. The company, which said it already is in discussions with investors about a potential second round, plans to use the proceeds to support the launch of its technology platform. The technology, which uses an endoscopic tool to spray extreme cold liquid nitrogen, is currently being used to treat esophageal disease at nearly 80 U.S. cancer centers and academic teaching hospitals.
http://www.csamedical.com
http://www.prnewswire.com/news-releases/csa-medical-completes-126-million-series-a-financing-with-additional-venture-investment-from-blue-heron-capital-125410798.html

Blacksburg-Based Intrexon Raises $100 Million in Fifth Round

Blacksburg, Va. — Intrexon, a Blacksburg-based life sciences firm developing technology to control the delivery and targeting of cancer drugs, said on Tuesday it has raised $100 million in its fifth round of funding, increasing its total backing to $259 million since 1998. The company said unnamed new investors took the majority of the round, with previous backers, including CEO Randal Kirk and Third Security also participating. Intrexon said the funding will provide working capital for its six commercial divisions — including its newly launched AgBio and Animal Science divisions — as well as help it expand its core UltraVector technology platform. “The success of the raise, including the valuation that Intrexon was able to attain, speaks strongly in favor of our business model and the opportunity that synthetic biology represents,” said Kirk. The closing of the round comes just weeks after the company completed acquisitions of Agarigen and Neugenesis.
http://www.dna.com
http://www.dna.com/20110531

Rockville-Based Supernus Raises $42 Million to Prepare Drugs for Launch

Rockville, Md. — Supernus Pharmaceuticals, a Rockville-based specialty pharmaceutical firm developing treatments for disorders of the central nervous system, said on Friday it has raised $42 million through a pair of transactions. The company said it generated $27 million from the sale of its TCD Royalty unit, as well as another $15 million from the issuance of venture debt. Supernus said it will use the proceeds to prepare for the commercial launch of its two lead product candidates in epilepsy, as well as to further develop its pipeline. “We have been able to raise more than $165 million through a series of five non-dilutive financing,” said Jack Khattar, the company’s president and CEO.
http://www.supernus.com
http://www.businesswire.com/news/home/20120106005025/en/Supernus-Pharmaceuticals-Raises-42-Million-Prepare-Launch